Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies GlobeNewswire - Thu Jun 4, 7:00AM CDT

Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully Collaboration focuses on education...

SPRY : 8.56 (-5.62%)
Canadian CPI Featured in Short Week Baystreet - Sun May 17, 4:17PM CDT

Monday U.S. Featured Earnings Baidu Inc (NASDAQ:BIDU) (Q1) EPS of $1.50, compared to ...

NVDA : 205.10 (-6.20%)
DE : 583.44 (-1.40%)
BEKE : 16.08 (-3.25%)
SPRY : 8.56 (-5.62%)
TJX : 160.71 (+1.31%)
ADI : 401.39 (-6.38%)
BIDU : 121.66 (-9.75%)
TCOM : 47.69 (-0.77%)
MUFG : 19.91 (-0.70%)
KEYS : 329.83 (-3.87%)
HTHT : 45.00 (+0.54%)
HD : 310.78 (+0.27%)
MarketBeat.com
ARS Pharmaceuticals Q1 Earnings Call Highlights MarketBeat - Fri May 15, 11:09AM CDT

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy,...

SPRY : 8.56 (-5.62%)
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Fri May 15, 5:00AM CDT

Q1 2026 total revenue of $22.7 million including  neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process;...

SPRY : 8.56 (-5.62%)
ARS Pharmaceuticals Revenue Accelerates but the Burn Rate Keeps Getting Worse Barchart - Thu May 14, 4:01PM CDT

Barchart Research What to Expect from SPRY Earnings SPRY Generated May 14, 2026 Current Price $7.94 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.26% ARS Pharmaceuticals Revenue Accelerates...

SPRY : 8.56 (-5.62%)
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President GlobeNewswire - Wed May 13, 7:00AM CDT

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe...

SPRY : 8.56 (-5.62%)
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results GlobeNewswire - Thu May 7, 7:00AM CDT

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients...

SPRY : 8.56 (-5.62%)
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) GlobeNewswire - Wed Apr 15, 5:05AM CDT

neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market ...

SPRY : 8.56 (-5.62%)
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label GlobeNewswire - Fri Mar 27, 7:00AM CDT

Children were previously required to weigh ≥33 lbs. and

SPRY : 8.56 (-5.62%)
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization GlobeNewswire - Mon Mar 9, 5:00AM CDT

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0...

SPRY : 8.56 (-5.62%)

Barchart Exclusives

Microsoft Announces Majorana 2 Quantum Chip as Wedbush Calls It Another ‘Validation’ for the Industry Barchart - 13 minutes ago
Microsoft declared its Majorana 2 topological quantum processor, a second-generation chip aimed at significantly improving qubit reliability and scalability. Wedbush described it as 'another validation' for the broader quantum computing industry. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.